15 December 2020
Latham & Watkins Advises on Financing for EQT’s US$2.1 Billion Bid to Acquire Recipharm
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Dominic Newcomb Lead | Latham & Watkins LLP | Partner | Not stated | London |
| Jennifer Engelhardt Lead | Latham & Watkins LLP | Partner | Not stated | London |
| Will Lam | Latham & Watkins LLP | Counsel | Not stated | Not stated |
| Melanie Emmen | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Medha Vikram | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Manoj Tulsiani | Latham & Watkins LLP | Partner | capital markets | London |
| Amina Tsatiashvili | Latham & Watkins LLP | Associate | Not stated | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 2.10bn (US$2.1 billion)
- What the figure measures
- Total transaction value
- Client
- Latham & Watkins
- Counterparties
- EQT (Buy-side)
Recipharm (Target)